Numbers

The Numbers

Centene trades where it does because the market believes its $195B revenue base is real but its earnings power is not yet trustworthy. The company is the largest Medicaid and Marketplace insurer in the country, but FY2025 exposed the central risk in managed care: medical costs and risk-adjustment assumptions moved faster than pricing, HBR rose to 91.9%, and a $6.7B goodwill impairment turned a thin-margin business into a reported loss. Management's 2026 HBR guide of 90.9%-91.7% says recovery is gradual, not a snapback; the single metric most likely to rerate or derate the stock is HBR, because each 100 bps of medical-cost improvement on this revenue base can move operating earnings by roughly $2B.

At a Glance

Centene is a government-sponsored managed-care spread business: it collects premium revenue, pays medical claims, and keeps a narrow administrative and underwriting margin. Medicaid is the core at 57% of external revenue, while Marketplace and Medicare carry the rerating risk because morbidity, subsidies, Star ratings, and Part D design can change quickly.

Quality Scorecard

Is this a well-run business that will still be around in 10 years?

The scorecard says Centene is liquid enough to survive the reset, but not clean enough to deserve a quality multiple. Cash generation and a near-neutral net debt position are the offset; reported profitability, earnings predictability, and policy sensitivity are the problem.

Revenue and Earnings Power

Revenue has compounded through acquisitions and premium growth, but operating income never scaled with it; the business still earns, or loses, money in small basis-point increments. The FY2025 impairment explains the depth of the loss, but the margin chart shows the broader issue: post-WellCare margins have not rebuilt to the 3% level Centene used to reach.

Revenue growth accelerated to more than 20% in Q2 and Q4 FY2025 even as membership fell, which means rate and mix carried the top line. The problem is that premium growth did not keep HBR low enough to protect earnings.

Cash Generation

Trailing 5-year FCF-to-net-income conversion is 10.4x because the FY2025 goodwill charge nearly erased cumulative GAAP net income; excluding the impairment year, FY2020-FY2024 conversion was 192%. Capex is structurally light, usually under 1% of revenue, so the cash question is working-capital timing and HBR, not plant investment.

Capital Allocation

The acquisition-financing era is visible in 2018-2021, while 2022-2025 shows financing outflows from deleveraging and repurchase activity. SBC is modest at roughly $0.2B per year, and Centene does not have a regular common dividend, so capital allocation discipline now depends on debt reduction and not chasing another large deal.

Balance Sheet Health

Centene ended FY2025 with slightly more cash than debt, so the balance sheet is not the immediate problem. The stress is in the equity base: goodwill impairment cut shareholders' equity to $20.0B and pushed liabilities-to-equity higher, keeping the Altman Z-Score in the grey zone.

Valuation vs History

Current forward P/E of 13.8x is below the 5-year mean of 14.8x and far below the 20-year mean of 50.2x, but the early years distort the 20-year average because EPS was small. Against the more relevant 2019-2024 post-scale period, CNC trades near normal, not obviously distressed on forward EPS alone; the discount is really in P/S and trust in the recovery.

The current forward P/E is 0.9 standard deviations below the 20-year mean, so it is below history but not a one-standard-deviation outlier. The consensus target is only 4% above the latest close, which says the market is already pricing a base-case recovery, not a clean value dislocation.

Peer Comparison

CNC is the cheapest large managed-care peer on P/S because it combines the lowest trust in normalized margins with direct exposure to Medicaid, Marketplace, and Medicare policy resets.

Fair Value and Scenario

Bear case is a 12-14x multiple on about $2 of stressed 2026 EPS if HBR stays around 92% and Marketplace morbidity remains worse than priced. Base case is roughly the consensus target, using $3 of adjusted EPS guidance at about 15x. Bull case requires operating margin moving back toward 2%, adjusted EPS recovering to $5-6 over time, and the stock regaining a low-to-mid teens earnings multiple.

The numbers confirm that Centene is still a massive, cash-generative managed-care platform with low capex needs and enough liquidity to absorb the 2025 reset; they contradict the simple "one-time charge only" narrative because margins and HBR also deteriorated before the impairment. Watch next quarter's HBR and Marketplace commentary: a print below 91% would support the 2026 recovery path, while another quarter above 92% would make the base case too generous.